Patent · US Active

Conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof

US11872283B2 · kind B2 · utility

0Cited by
16References
20Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJul 9, 2019
Grant dateJan 16, 2024
Priority date
Expiry dateFeb 29, 2040

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2319/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention relates to a conjugate comprising oxyntomodulin, an immunoglobulin Fc region, and non-peptidyl polymer wherein the conjugate being obtainable by covalently linking oxyntomodulin to immunoglobulin Fc region via non-peptidyl polymer, and a pharmaceutical composition for the prevention or treatment of obesity comprising the conjugates. The conjugate comprising oxyntomodulin and the immunoglobulin Fc of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis without side-effects, unlike native oxyntomodulin, and also shows excellent receptor-activating effects and long-term sustainability, compared to native oxyntomodulin. Thus, it can be widely used in the treatment of obesity with safety and efficacy.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.